Managers / Q4 2025 · view latest →
Enavate Sciences GP, LLC
CIK 0001953107 · 106 W 56TH ST., FLOOR 8, NEW YORK, NY, 10019 · 212-909-3022
Summary
Enavate Sciences GP, LLC reported $507M in U.S.-listed holdings across 7 positions for Q4 2025.
The portfolio is heavily concentrated: ZBIO alone accounts for 28.1% of reported value.
The book was largely unchanged from Q3 2025.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $507M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CAMPCAMP4 THERAPEUTICS CORP | TRIMMED | −750.0K | 3.04M | +$7M | $19M |
| ZBIOZENAS BIOPHARMA INC | HELD | +157.8K | 3.92M | +$59M | $142M |
| IMNMIMMUNOME INC | HELD | +0 | 4.77M | +$47M | $102M |
| SIONSIONNA THERAPEUTICS INC | HELD | +0 | 2.48M | +$29M | $102M |
| UPBUPSTREAM BIO INC | HELD | +0 | 2.46M | +$21M | $67M |
| CMPXCOMPASS THERAPEUTICS INC | HELD | +0 | 7.79M | +$15M | $42M |
| BBOTBRIDGEBIO ONCOLOGY THERAPEUT | HELD | +0 | 2.63M | +$2M | $33M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ZBIOZENAS BIOPHARMA INChistory → | COM | 28.08% | $142M | 3.92M |
| 2 | IMNMIMMUNOME INChistory → | COM | 20.21% | $102M | 4.77M |
| 3 | SIONSIONNA THERAPEUTICS INChistory → | COM | 20.12% | $102M | 2.48M |
| 4 | UPBUPSTREAM BIO INChistory → | COM | 13.18% | $67M | 2.46M |
| 5 | CMPXCOMPASS THERAPEUTICS INChistory → | COM | 8.25% | $42M | 7.79M |
| 6 | BBOTBRIDGEBIO ONCOLOGY THERAPEUThistory → | COM NEW | 6.49% | $33M | 2.63M |
| 7 | CAMPCAMP4 THERAPEUTICS CORPhistory → | COM | 3.67% | $19M | 3.04M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $352M | 7 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $507M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $328M | 7 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $177M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $133M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $139M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.